A Multi-Center Phase II Study to Evaluate the Efficacy and Safety of AMN107 (Nilotinib) in Patients With Gastrointestinal Stromal Tumors Who Have Progressed on or Are Intolerant to Both Imatinib and Sunitinib.
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2017
At a glance
- Drugs Nilotinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Novartis
- 27 Mar 2014 Planned End Date changed from 1 Jun 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov record.
- 27 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Jun 2012 New source identified and integrated (German Clinical Trials Register DRKS00003938).